Cognito Therapeutics Showcases Spectris™ for Alzheimer's Innovation
Upcoming Presentation at CTAD 2024
Cognito Therapeutics, a pioneering neurotechnology firm, is set to showcase new data concerning its innovative therapy Spectris™ in treating Alzheimer’s disease. This significant event, which will take place at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, highlights Cognito’s commitment to advancing disease-modifying treatments aimed at Central Nervous System (CNS) disorders.
About Spectris™ and Its Impact
Christian Howell, the CEO of Cognito Therapeutics, expressed enthusiasm about the upcoming presentations, which underscore the promising potential of Spectris™ in preserving both brain function and structure among Alzheimer's patients. “Our recruitment strategies for the HOPE trial have enabled us to evaluate a diverse and representative group of Alzheimer's individuals,” stated Howell. He emphasized the company's continuous commitment to enhancing this non-invasive therapy for those affected by Alzheimer's.
Clinical Significance of the Findings
Ralph Kern, M.D., MHSc, Cognito's Chief Medical Officer, added that Spectris™ has demonstrated notable success by employing non-invasive auditory and visual neuromodulation techniques. The collected data show not only clinically meaningful results but also ensure the preservation of daily functions and overall brain structure.
Details of the Poster Presentations
The following poster presentations will be featured at the CTAD conference:
- Abstract Title: SPECTRIS™ Treatment Reduced Alzheimer’s Disease Dependence Score in OVERTURE I/II Phase 2 Study
Format: Poster 025
Presenter: Marwan Sabbagh, MD, Barrow Neurological Institute
Session Name: Poster Session 1
Date/Time: Tue Oct 29 at 3:00 pm - Wed Oct 30 at 5 pm - Abstract Title: SPECTRIS™ OVERTURE I responder analysis demonstrates consistent preservation of function and brain structure.
Number: Poster 026
Presenter: Ralph Kern, M.D., MHSc, Chief Medical Officer, Cognito Therapeutics
Session Name: Poster Session 1
Date/Time: Tue Oct 29 at 3:00 pm - Wed Oct 30 at 5 pm - Abstract Title: Clinical Trial Enrichment Strategy for Participant Selection in the Phase 3 HOPE study of Alzheimer's disease: Progress towards personalized medicine
Poster Number: LP005
Presenter: Lily Lee, Ph.D., Vice President and Head of Medical Affairs, Cognito Therapeutics
Session Name: Poster Session 1
Date/Time: Tue Oct 29 at 3:00 pm - Wed Oct 30 at 5 pm - Abstract Title: Diversity amongst the Phase 3 HOPE study participants is reflective of the real-world Alzheimer’s Disease (AD) population
Poster Number: LP 099
Presenter: Ralph Kern, M.D., MHSc, Chief Medical Officer, Cognito Therapeutics
Session Name: Poster Session 3
Date/Time: Fri Nov 1 at 7:15 am - 5 pm - Abstract Title: Comparison of visually evoked steady-state oscillations between two Spectris™ eyesets
Poster Number: LP 028
Presenter: Mihaly Hajos, Ph.D., Chief Science Officer, Cognito Therapeutics
Session Name: Poster Session 1
Date/Time: Tue Oct 29 at 3:00 pm - Wed Oct 30 at 5 pm - Abstract Title: Effects of sensory-evoked gamma oscillation on neurophysiological signals of visual and cognitive processing in Alzheimer’s disease
Poster Number: LP 016
Presenter: Mihaly Hajos, Ph.D., Chief Science Officer, Cognito Therapeutics
Session Name: Poster Session 1
Date/Time: Tue Oct 29 at 3:00 pm - Wed Oct 30 at 5 pm
About Cognito Therapeutics
Cognito Therapeutics is a cutting-edge clinical neurotechnology company leading the way in developing disease-modifying treatments for neurodegenerative conditions. Their flagship product, Spectris™, utilizes innovative, non-invasive auditory and visual neuromodulation techniques aimed at enhancing gamma frequency brain activity. This innovative approach strives to mitigate brain atrophy and functional decline in patients with Alzheimer’s disease. The company is devoted to creating transformative, technology-driven solutions catering to the unmet needs of those suffering from CNS-related disorders. Cognito is headquartered in Cambridge, MA, where it continues to push the boundaries of neurotechnology interventions.
Frequently Asked Questions
What is the significance of the CTAD conference?
The CTAD conference is a major event focused on new scientific discoveries in Alzheimer's disease and therapies, providing a platform for researchers and companies to share significant advancements.
What is Spectris™?
Spectris™ is a non-invasive therapy developed by Cognito Therapeutics that utilizes auditory and visual stimulation to target brain activity, aiming to slow Alzheimer's progression.
Who is presenting on behalf of Cognito Therapeutics?
Several key figures from Cognito, including Christian Howell, Ralph Kern, and Marwan Sabbagh, will present data related to Spectris™.
What are some findings from the HOPE study?
The HOPE study has shown promising results with Spectris™, demonstrating consistent preservation of brain functions and structure among diverse populations.
How does Cognito Therapeutics approach Alzheimer's treatment?
Cognito Therapeutics focuses on pioneering non-invasive treatments and enhancing the quality of life for Alzheimer’s patients through innovative neurotechnology solutions.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Innovations and Trends in the Specialty Lighting Market
- Tricolor's Bold Move: A $288M Social Bond for Inclusion
- US LBM Foundation Pledges Half Million for Hurricane Relief
- Investigation of JFrog Ltd. Raises Concerns for Investors
- Blue Diamond Growers Earns Star Site Award for Safety Excellence
- Key Deadline Approaches for Extreme Networks Investors
- Duke Energy Declares Quarterly Dividend Payments for Shareholders
- Exploring Salesforce's Recent Options Activity and Insights
- California's Initiative to Uplift Youth Sports Coaches by 2025
- Fortuna Mining Secures Future with Yaramoko Permit Validity
Recent Articles
- Innovative Dining Experience at Resorts World Las Vegas
- Zyxel Unveils Advanced Fiber Solutions at WISPAPALOOZA 2024
- Rivian: The Next EV Giant on the Investment Horizon
- Included Health Achieves URAC Case Management Accreditation
- Exploring New Advances in Systemic Lupus Erythematosus Treatment
- Zurn Elkay Water Solutions Earns Recognition for Sustainability Efforts
- Innovid Unveils Guide to Transform Holiday Advertising
- Nissan Joins ChargeScape: A New Era for EV Owners
- Automated Industrial Robotics Expands Portfolio with RDS Acquisition
- Rocket Lab Set for Mars Mission Study Contract with NASA
- InterVene Secures $13 Million to Advance Innovative Venous Solutions
- Orion Energy Systems Secures Major LED Lighting Contract
- Unlocking Investment Opportunities: Arta Finance's Impact
- Rathbones Group Analysis: Insights on Balanced Commercial Property Trust
- Supporting Local Artists: The Record Co.'s AMPLIFY BOSTON Campaign
- LightBox CRE Activity Index Sees Positive Response to Rates
- Sibelco's Commitment: $1 Million Donation and Foundation Launch
- Trulieve Launches New Dispensary, Enhancing Patient Access
- Softchoice to Reveal Third Quarter 2024 Financials Soon
- Investors Can Lead a Class Action Against Bumble Inc. BMBL
- Elevance Health Upcoming Call Highlights Q3 2024 Financials
- Power Metals Corp. Reports Significant Cesium Findings
- Understanding Barnes Group Inc.'s Shareholder Rights and Concerns
- Concerns Rise Over Duckhorn Portfolio's Shareholder Value
- IceCure's ProSense® Shines in Global Breast Imaging Studies
- Innovation Beverage Group Announces New CSO Genevieve Jodhan
- Haoxi Health Technology Limited Projects Impressive Revenue Growth
- Diversified Healthcare Trust Conference Call Highlights and Details
- Trex Company Sets Date for Q3 Earnings Call Announcement
- Upcoming Earnings Announcement from Flexsteel Industries, Inc.
- Deckers Outdoor Faces Downgrade but Shows Promising Growth Ahead
- A10 Networks Set to Unveil Q3 2024 Financial Performance Details
- NIP Group Welcomes New Director Randy Hearst Harris
- IceCure Medical Showcases ProSense® Breakthroughs at EUSOBI
- Revvity's Upcoming Earnings Call Promises Insight for Investors
- Akoya Biosciences' Role in Advancing Cancer Research Efforts
- Fortune Minerals Collaborates with Worley for NICO Project Enhancement
- Worksport Sets Ambitious Goals with New Product Launches
- Freedman Normand Friedland Enhances Legal Services in Art Law
- Ultragenyx's Setrusumab Receives FDA Breakthrough Therapy Nod
- MG Digital Direct Enhances Marketing with Advanced Solutions
- Commercial Real Estate Sees Renewed Interest Following Rate Cuts
- CDK Global Deepens Ties with AutoCanada, Enhancing Dealerships
- Eternity Technology Partners with Connexa for AI Innovations
- Exiger Partners with AHA to Strengthen Cybersecurity in Healthcare
- Vapor IO Launches Innovative AI-Powered 5G Network in Las Vegas
- Mizuho Adjusts CVR Energy Price Target Amid Market Challenges
- Barclays Upgrades Global Payments Rating Amid Growth Strategy
- Tour24 and Brivo Team Up for Enhanced Self-Guided Tours
- Rivian's Path Ahead: Challenges and Growth Opportunities